亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台，协助业界发掘知识产权贸易商机，并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权，或是制造商需要购买技术以提高操作效能，又或是知识产权配套服务供应商，你将会从本网站发掘到有用的知识产权贸易资讯。

返回搜索结果

Synthetic Platelets (SynPlats) to Treat Internal & External Bleeding

技术优势: • Non-surgical treatment of internal bleeding• Can be used in combination with current hypovolemia treatments• Increased efficiency in treating hypovolemia

技术应用: • Treatment of hypovolemia and prevention of exsanguination• Tool to control blood loss in emergency medicine

详细技术说明: Researchers at the University of California, Santa Barbara have developed a nanoscale synthetic hemostatic agent inspired by the design of natural platelets. SynPlats were synthesized via layer-by-layer assembly of globular proteins on a polymer template to yield capsules mechanically and morphologically similar to circulatory cells. These SynPlats can be specialized for a variety of roles by linking function-promoting peptides. In particular, hemostasis-promoting peptides were used to direct SynPlats to affected areas where they can begin the clotting process. Through extensive testing, these synthetic platelets have proven to reduce bleeding time internally and externally by as much as 65%. SynPlats offer a novel nanomaterial that mimics the function of natural platelets and offers a new tool in emergency medicine. Figure: Hemostatic mechanism of synthetic nanoplatelets. Schematic showing endothelial damage: red blood cells flowing out of the wound at time = 0s and primary platelets interacting with synthetic nanoplatelets forming the hemostatic plug at following injury. LINK TO PUBLICATION: http://pubs.acs.org/doi/abs/10.1021/nn503732m

*Abstract: Biomaterial nano-particles that mimic the key structural and functional attributes of platelets and have been shown to greatly reduce bleeding time both internally and externally.

*Applications: • Treatment of hypovolemia and prevention of exsanguination

*Principal Investigation: Name: Aaron Anselmo
Department:

Name: Stefano Menegatti
Department:

Name: Samir Mitragotri
Department:

其他

Background

Exsanguination, the complete loss of blood, causing death, is responsible for 3 million deaths worldwide due to trauma, and is the leading cause of death in the military. Hemostatic agents are currently used to control excessive bleeding, however this method is not always effective. Today’s hemostatic agents are externally administered in the form of a hemostatic-containing gauze pad, which limits treatment of excessive bleeding to solely externally accessible wounds. The only treatment available to stop internal bleeding is surgery, and the control of bleeding is essential and critical in surgical procedures to minimize blood loss, reduce post-surgical complications, and to shorten the duration of the surgery in the operating room. Exsanguination is one of the leading preventable causes of death, indicating that new advancements in technology are needed to treat hypovolemia — a state of decreased blood volume — and reduce the death count by exsanguination.

Additional Technologies by these Inventors

Tech ID/UC Case

24143/2014-452-0

Related Cases

2014-452-0, 2010-419-0

国家/地区: 美国

欲了解更多信息，请点击这里